Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
about
New advances in targeted gastric cancer treatmentDoublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis of 10 Randomized Controlled TrialsAdvanced gastric cancer: Current treatment landscape and future perspectivesNovel targets in the treatment of advanced gastric cancer: a perspective reviewCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationTargeted therapy for advanced gastric cancer: A review of current status and future prospectsChanging strategies for target therapy in gastric cancerGastric Cancer: New Drugs - New StrategiesSecond- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysisMolecular classifications of gastric cancers: Novel insights and possible future applications.Indian Council of Medical Research consensus document for the management of gastric cancerEfficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinomaEfficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system reviewS-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 TrialTBL1XR1 Is Highly Expressed in Gastric Cancer and Predicts Poor PrognosisTreatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experienceDistal gastrectomy versus total gastrectomy for distal gastric cancer.Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithmGastric cancer management: Kinases as a target therapy.Second-line chemotherapy for patients with advanced gastric cancer.Chemotherapy for advanced gastric cancer: future perspective in Japan.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?Gastric adenocarcinoma.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis.The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.Current therapeutic landscape for advanced gastroesophageal cancers.Molecular Signaling in Tumorigenesis of Gastric CancerIrinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.New therapeutic options opened by the molecular classification of gastric cancer.Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer
P2860
Q26738548-206C5F4F-487A-478E-95B5-5139CDFF8D63Q26764802-F222CCEA-E2A4-4885-B3C2-149951973AE8Q26764934-9DE92BCB-3DA3-4348-A583-7B46E7084501Q26765208-782D7003-66EB-4D63-A732-978D2FD49E7FQ26765941-2C20D0C4-D9B9-4C94-BCF3-9C24D3F929DCQ26774138-2EF9E7FA-168D-4564-8BB2-89EED93BE3E4Q26774513-4880299B-B6BB-455A-B4B7-9528D0F448DAQ27028079-68028D4B-F06D-48E0-BC1E-6F2A6017A9F8Q30249003-3BE0E996-2B20-4A07-AAC9-0AA3AA52CADEQ33441654-A67A22A6-4AFA-461E-9A7B-0B86B9F931A5Q33696201-EBA51167-6E64-46D0-89BD-F0FA5A2AD095Q34686187-438D3FF5-5F73-43E7-99B6-9746FF9711E1Q35948006-F8B7B969-3985-4A9D-B425-F86C12747B3AQ36134904-B5A69E2B-371B-4FCB-A581-BA0E52F70528Q36194219-E366F2FF-2629-4279-9AD0-40E255EB0984Q37273742-26963146-7B6D-446E-A05A-BD3E06373FA4Q37362948-D62F0674-112E-4D43-9BE2-288A49AA2B19Q37626654-CCF301CB-D5F2-4D33-820B-5E8568E55F25Q37687784-84DBE0C0-E83A-4671-B92D-58B0C40D169AQ38749038-95D30BFA-5674-4542-BC41-31EDA823DB07Q38750633-23474920-85FF-4234-A94A-B551C011D371Q38815071-B3A5BCFA-5C32-4A05-A318-3579D2073194Q38823374-6FA9EF86-BB35-45D8-B749-6D52D052D86FQ38939088-43BEED01-5A45-4010-BD8E-5EB06EB512DFQ39343374-321BDA82-ECF7-451B-92C9-5582D9D5C5A6Q39344380-208352C2-107A-42CC-AC78-364007C83851Q42265610-D8A51644-6E92-465E-BDC3-FFA3B11726B5Q47120612-FB51E94C-2DFA-43BB-8416-E1B4FBAF9ECCQ47402625-97653B14-4A1D-4367-A2B3-F3B69A9258EDQ48226075-2662ADE7-1D12-46BD-AB53-9AE9BECD6224Q52581752-1B49262C-85C7-49AE-9B86-A01810D03BFEQ55429664-D05BB2E4-F182-483A-B574-A06AF7AF0157Q55496231-1ED95CDB-208D-4F2B-A835-B127ED843269Q55527185-DCAB5745-ACF7-4FA3-8F2D-BC4BD5625108Q58720903-DA675759-1E7F-4648-AEFD-D1EB8F877F95
P2860
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Randomized phase II trial of n ...... s with advanced gastric cancer
@ast
Randomized phase II trial of n ...... s with advanced gastric cancer
@en
type
label
Randomized phase II trial of n ...... s with advanced gastric cancer
@ast
Randomized phase II trial of n ...... s with advanced gastric cancer
@en
prefLabel
Randomized phase II trial of n ...... s with advanced gastric cancer
@ast
Randomized phase II trial of n ...... s with advanced gastric cancer
@en
P2093
P2860
P1433
P1476
Randomized phase II trial of n ...... s with advanced gastric cancer
@en
P2093
Eriko Yamamoto
Hirofumi Yasui
Jung-mi Kim
Kazuto Nishio
Kensei Yamaguchi
Kyung Hee Lee
Masaki Munakata
Nozomu Fuse
Qingwei Zhang
Satoshi Morita
P2860
P2888
P304
P356
10.1007/S10120-014-0420-9
P577
2014-09-05T00:00:00Z